A Combination of Avutometinib Plus Defactinib Results in Clinically Meaningful Benefit in Patients with Recurrent Low-Grade Serous Ovarian Cancer By Ogkologos - August 5, 2025 797 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ENGOT-OV60/GOG-3052/RAMP 201 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Expanding Research on Dormant Cancer Cells Aims to Prevent Metastasis April 10, 2025 Multiple Myeloma Awareness Month: Inequity and Disparities in Multiple Myeloma Diagnosis,... March 1, 2021 France Bans all Textured and Polyurethane Breast Implants Amid BIA-ALCL Cancer... April 5, 2019 Sacituzumab Govitecan Demonstrates Overall Survival Benefit Over Chemotherapy in Patients with... September 18, 2023 Load more HOT NEWS Reflections from our chief clinician: The essential role of our research... Ending smoking could free up 75,000 GP appointments each month Researchers Create Modified Antibodies to Target RAS and p53 in Cancer Prising open the trap: Getting to grips with targeted cancer drug...
